| Author/Editor | Artemchuk, Hanna; Eriksson, Tiina; Poljak, Mario; Surcel, Heljä-Marja; Dillner, J.; Lehtinen, Matti; Faust, Helena | |
| Title | Long-term antibody response to human papillomavirus vaccines | |
| Type | članek | |
| Vol. and No. | Letnik 219, št. 4 | |
| Publication year | 2019 | |
| Volume | str. 582-589 | |
| ISSN | 0022-1899 - The Journal of infectious diseases | |
| Language | eng | |
| Abstract | Background. Most cervical cancers are caused by vaccine-preventable infections with human papillomaviruses (HPV). The HPV prophylactic vaccines Gardasil and Cervarix have been widely used for >10 years and are reported to induce high antibody levels. A head-to-head comparison of the antibody responses induced by the 2 vaccines has been performed only up to 5 years.Methods.Among 3300 Finnish females aged 16-17 years who got 1 of the 2 HPV vaccines in phase 3 licensure trials, virtually all consented to registry-based long-term follow-up. Linkage with the Finnish Maternity Cohort found that they donated >2500 serum samples up to 12 years later. Sera of 337 (38.6%) Gardasil and 730 (30.3%) Cervarix vaccine recipients were retrieved from the Finnish Maternity Cohort biobank and type-specific anti-HPV antibody levels were determined using in-house multiplexed heparin-HPV pseudovirion Luminex assay.Results.Anti-HPV-16 and anti-HPV-18 antibody levels remained stable and above natural infection-related antibody levels for up to 12 years for most vaccine recipients. The median antibody levels were higher among Cervarix recipients 7-12 years post vaccination (P < .0001).Conclusions.The stability of vaccine-induced antibody levels is in accordance with the high long-term protection reported previously. The differences in antibody levels induced by the 2 vaccines imply that continued follow-up to identify possible break-through cases and estimation of the minimal protective levels of serum antibodies is a research priority. | |
| Keywords | human papillomavirus (HPV) vaccine long-term follow-up antibodies cepivo proti humanemu papiloma virusu (HPV) dolgoročno spremljanje protitelesa |